Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications

• Authors: Adrian L Rabinowicz, Neurelis Inc; Edward Faught, Emory University; David F Cook, Neurelis Inc; Enrique Carrazana, Neurelis Inc
• Journal Title: NEUROPSYCHIATRIC DISEASE AND TREATMENT
• Volume: Volume 18
• Publisher: DOVE MEDICAL PRESS LTD | 2022-01-01, Pages 2431-2441
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.2147/NDT.S376104
• Subjects: Health Sciences, Medicine and Surgery
• Keywords: Science & Technology; Life Sciences & Biomedicine; Clinical Neurology; Psychiatry; Neurosciences & Neurology; diazepam; midazolam; nasal; rectal; acute repetitive seizures; twenty-four hours; DIAZEPAM RECTAL GEL; UNITED-STATES; EPILEPSY; PHARMACOKINETICS; INTRANASAL; CHILDREN; ADULTS; COSTS

Abstract

Purpose: People with epilepsy may experience seizure clusters despite a stable regimen of antiseizure medications. Such clusters have the potential to last ≥24 hours, typically occur in the community setting, and may progress to medical emergencies, such as status epilepticus, if untreated. Thus, long-acting rescue therapy for seizure clusters is needed that can be administered by nonmedical individuals outside a hospital. Benzodiazepines are the foundation of rescue therapy for seizure clusters. The approved outpatient treatments (ie, diazepam, midazolam) have differing profiles that may affect multiple aspects of health-care utilization. The current labeling of these medications allows for a second dose if needed to control the cluster. Although no head-to-head studies directly comparing rescue treatments have been conducted, differences between studies with generally similar designs may provide context for the potential importance of second doses of rescue therapy on health-care utilization. Methods: For this analysis, large, long-term, open-label studies of approved seizure-cluster treatments designed for use by nonmedical caregivers were reviewed, and the percentage of seizure clusters for which a second dose was used or that were not controlled at 6, 12, and 24 hours was examined. Available data on hospitalizations were also collected. Results: The 3 identified studies meeting the inclusion criteria were for use of diazepam rectal gel, intranasal midazolam, and diazepam nasal spray. Across these studies, the use of a second dose ranged from <40% at 6 hours to <13% at 24 hours. Hospitalizations and serious treatment-emergent adverse events were reported variably across these studies. Conclusion: These results demonstrate the importance of second doses of rescue therapy for seizure clusters for optimizing healthcare utilization. Need for second doses should be included as one component. In turn, when second doses are needed, they have the potential to curtail emergency department use and hospitalization and to prevent further seizure clusters.